Biotech News
Related news
CORTCorcept2026-04-23 20:05 EST
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORTCorcept2026-07-29 20:05 EST
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
VKTXViking Therapeutics2026-07-29 20:05 EST
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
VKTXViking Therapeutics2026-04-29 20:05 EST
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NBIXNeurocrine Biosciences2026-07-09 20:01 EST
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
NBIXNeurocrine Biosciences2026-04-14 20:01 EST
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
AMPHAmphastar Pharmaceuticals, Inc.2020-07-30 20:05 EST
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020
AMPHAmphastar Pharmaceuticals, Inc.2021-04-29 10:00 EST
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
Corcept
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...
Recent company news
CORTCorcept2026-07-29 20:05 EST
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
CORTCorcept2026-07-22 20:05 EST
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORTCorcept2026-06-17 20:28 EST
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
CORTCorcept2026-06-06 20:45 EST
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
CORTCorcept2026-05-29 20:33 EST
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Stock data
- Close
- 107.95 USD
- Market cap
- 7.64B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States